A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO
ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER

IRB/UVA Tracking #
19885
Contact First Name

Heather L Lothamer

Contact Email
Contact Phone
Phase
III
Primary purpose
Treatment
Cancer PI
Charles N Landen
Status
OPEN TO ACCRUAL